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Abstract
Osteoarthritis (OA) is the most common joint condition worldwide. It can lead 
to chronic debilitating symptoms that can be definitively managed with surgical 
techniques at times. More frequently however, either due to age, extent of disease 
or patient choice, non-surgical approaches are preferred. They include topical 
therapies such as thermotherapy, ultrasound, laser treatment, non-steroidal 
anti-inflammatory drugs (NSAIDs) and capsaicin cream. Injections are another 
technique often implemented. These consist of intra-articular (IA) corticosteroid or 
hyaluronan injections, trigger point injections and subcutaneous sodium salicylate. 
Acupuncture and various types of external support are also widely used. This chap-
ter examines the latest evidence and summarises the role of the various regional 
treatments available for use in the management of OA.
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1. Introduction
Osteoarthritis (OA) is the most common chronic joint condition in the world 
and affects nearly 9 million people in the United Kingdom alone [1]. It manifests 
clinically as localised joint pain, stiffness and occasionally swelling.
OA can occur as a primary idiopathic phenomenon with no prior causative trauma, 
although more frequent are cases of secondary OA appearing as a result of pre-
existing joint damage [2]. This is often in the context of inflammatory arthropathy or 
previous injury. Risk factors for primary OA include advancing age, female sex, family 
history and obesity [1–3]. The disease can be restricted to a single joint or become 
more widespread, affecting multiple joints. In severe cases, it can progressively lead to 
significant deformity, loss of function and a reduced quality of life [1, 4].
Treatment has mainly focused on symptomatic relief from pain, physical 
approaches such as rehabilitation and physiotherapy, disease-modifying treatment 
(such as hydroxychloroquine) and surgery. Pain relief with systemic drugs has draw-
backs. In particular, the use of non-steroidal anti-inflammatory drugs (NSAIDs) has 
been associated with significant adverse events including gastritis and increased risk 
of cardiovascular disease. In view of this, there has been increased interest in local-
ised treatments for OA; specifically, therapies that are localised to the affected joint 
itself. These can be divided into topical treatment, such as anti-inflammatory gels, 
creams and thermotherapy, and more invasive local treatment including joint aspira-
tion and intra-articular (IA) joint injection with corticosteroid and hyaluronans.
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2. Topical treatments
2.1 Thermotherapy
Thermotherapy refers to the application of either heat or cold (cryotherapy) to 
affected joints in an attempt to improve pain, stiffness and swelling.
Ice massage and the application of ice packs have both been studied in knee 
osteoarthritis [5–10]. It is likely that most of the observed effects of cryotherapy 
are related to the induction of local vasoconstriction. This leads to a reduction in 
blood flow, lower levels of local inflammation and reduced swelling. In one review 
[7], cryotherapy was found to reduce pain, stiffness and oedema. Regular ice 
massage, given five times a week, led to clinically significant effects on all three 
symptoms as well as function, strength and range of movement over a 2-week 
period [8]. However, these improvements were not replicated with less frequent 
applications (three times per week) [9]. There are no data to indicate a sustained 
effect of cold therapy on osteoarthritis as these studies looked only at a limited 
duration of therapy.
Common methods of superficial heat administration include the use of 
electrical heating pads, heat packs, towels or wax. Immersion in warm water or 
wax baths has also been shown to provide some subjective benefit. In some early 
trials, heat application failed to improve function or symptoms [8, 9]. In recent 
years, however, various studies have investigated different modalities of local 
heat therapy [10–13]. These include the application of heat packs [12], ultra-
sound [11, 13] and diathermy. The application of local heat packs has been found 
to provide short-lived alleviation of pain [12, 14], and in particular, wet heat 
(involving liquids) has been found to be better than dry heat [15] for symptomatic 
improvement.
In one study [12] 18 patients were randomised into two groups that received dif-
fering therapy over a course of 12 weeks. One was treated with application of steam 
generating heat sheets for 6 hours each day, and the other performed a daily quadri-
ceps strengthening exercise regime. At the end of the study, patients in the heat-
treated group reported statistically significant improvements in their symptoms 
and objective “Up and Go” times (a measure of function). The mechanism of heat 
therapy in osteoarthritis is unclear, although ex vivo studies of cartilage [15, 16] 
have indicated that elevating the temperature of chondrocytes may increase their 
metabolism and the production of proteoglycans that are major components of 
cartilage in combination with collagen. This, in part, may be secondary to increased 
blood flow to the chondrocytes.
On the whole, the available data suggest that thermotherapy may be useful as 
an adjunct in the treatment of osteoarthritis, although long-term benefits have not 
been established, and there are no robust clinical trials evaluating its efficacy.
2.2 Local ultrasound therapy
The role of ultrasound (US) in diagnosis of musculoskeletal problems is well 
established. Its popularity is in large part due to the low cost and non-invasive 
nature of the modality. In recent years, there has been growing interest in its 
application for therapeutic purposes [13, 17–19]. In theory, direct treatment with 
US leads to local heating of the tissue at depths not achieved by applying heat packs. 
There are two main techniques utilised: continuous US which leads to a rise in 
temperature of the treated tissues, enhancing fibrous tissue extensibility [20] and 
promoting capillary permeability [21] and pulsed wave treatment which harnesses 
nonthermal effects and is beneficial for cartilage health [18].
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In vitro and animal studies [17, 18] have suggested that pulsed wave US can 
increase collagen production and reduce expression of membrane metalloprotein-
ase, suggesting a protective role. However, this has failed to translate to long-term 
clinical benefit: randomised controlled studies [13, 19] comparing continuous, 
pulsed and sham US on knee osteoarthritis symptoms have shown no significant 
difference in pain scores nor function. In general, the safety of US has been estab-
lished, and anecdotal trends have been observed, but evidence is scarce for any 
significant therapeutic advantage [13, 19].
2.3 Laser therapy
Laser beam therapy directs intense light to treated tissue. Two types of laser 
therapy have been trialled in osteoarthritis: low-level and high-intensity. Low-level 
laser therapy (LLLT) uses red and infrared light wavelengths, whilst high-intensity 
laser therapy confers higher wavelengths of radiation for deeper tissue penetration. 
LLLT produces a photochemical rather than thermal response and has been found 
to reduce pain by modulating the local inflammatory process at a cellular level 
[22]. This involves the increased production of reactive oxygen species (ROS) and 
enables transcription of cellular components such as nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) that help modulate cell proliferation 
and growth (Figure 1).
In one rat model of osteoarthritis, laser therapy caused a reduction in neutrophil 
migration, oxidative stress, altered levels of cyclooxygenase-2 and other pro-
inflammatory mediators [24]. Another demonstrated that LLLT stimulates tissue 
repair and reduces the rate of extracellular matrix degradation [25]. There is also 
some evidence that LLLT promotes fibroblast proliferation, collagen synthesis and 
bone regeneration [26–31]. In a rabbit model of osteoarthritis, 6 weeks of treatment 
with laser therapy not only resulted in less pain but also histological evidence of 
reduced inflammation and cartilage damage [32].
This suggests that LLLT could have disease-modifying effects as well as symptom-
atic benefits, although the results of early clinical trials have been mixed thus far [33]. 
Figure 1. 
Mechanisms of low-level light therapy (reproduced from Ref. [23]). Abbreviations: ATP, adenosine triphosphate; 
ROS, reactive oxygen species; NO, nitric oxide; Jun/Fos, Jun and Fos protein subunits; IκB, inhibitor of kappa  
B; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; AP-1, activator protein-1.
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Recent studies have tended to be more positive with those treated with laser therapy 
and exercise faring better than those treated with exercise alone in terms of pain mea-
surements as well as function [34, 35]. These studies suggest that LLLT in combination 
with standard physiotherapy could provide advantages over standard therapy, and 
it shows potential as a non-invasive, safe and cost-efficient treatment modality [36]. 
Once again, however, evidence is lacking regarding long-term effects and whether the 
cellular effects seen modify disease progression.
2.4 Topical non-steroidal anti-inflammatory drugs
The mechanism of action of non-steroidal anti-inflammatory drugs is well-
known. They inhibit the action of cyclooxygenases (COXs) responsible for the 
synthesis of prostaglandins (PGs), which are recognised mediators of inflam-
mation [37]. Locally this reduces pain, swelling and heat. There is a large body of 
evidence in animal models of NSAIDs also providing central analgesic actions, with 
mechanisms involving spinal regulation of COXs and PGs as well as the induction 
of endogenous opioid peptides and blockade of serotonin release [38].
It is clear to see, therefore, why systemic NSAIDs have long been used in man-
agement of osteoarthritis. However, significant side effects including gastritis, 
renal impairment and increased risk of cardiovascular disease has meant that their 
long-term use has been limited. This has led to the promotion of topical NSAID use, 
theoretically providing local analgesic and anti-inflammatory benefits without the 
undesirable systemic adverse effects.
There are many types of topical NSAID. Preparations containing diclofenac, 
ibuprofen, piroxicam, ketoprofen or felbinac as the active ingredient all exist. Some 
include a penetration enhancer such as menthol or dimethyl sulfoxide (DMSO), 
whilst gels and sprays tend to be more penetrative than cream preparations. Once 
applied, a topical NSAID is absorbed by the underlying tissue or enters the local 
blood stream. Studies have shown that the absorption of NSAIDs into the underly-
ing tissue gives rise to therapeutic local concentrations of the drug without signifi-
cant systemic absorption [39, 40]. An estimated 3–7% of the applied dose is thought 
to be absorbed systemically [39] with plasma concentrations approximately 5% of 
those achieved with oral administration [39].
The skin acts as a reservoir from which the drug disseminates to the deeper 
tissue. Peak concentrations in the skin are achieved 2 hours after application with a 
further spike approximately 19 hours later, likely secondary to systemic absorption. 
Further proof of their local action is the absence of analgesic effect at joints distant 
to the point of application [41].
There have been many studies looking into the efficacy of topical NSAIDs in 
treating osteoarthritis [42–48]. On the whole, these have found topical NSAIDs 
to be superior to placebo in the treatment of chronic pain. Most of the initial 
studies found no benefit beyond 2 weeks of treatment [42–48], but larger ran-
domised controlled trials demonstrated long-term benefit for up to 3 months 
when compared to placebo [49, 50].
When compared to oral NSAID use, the results have been variable. A meta-
analysis in 2006 [48] found that topical NSAIDs were less effective than systemic 
NSAIDs. Since then, however, there have been several studies showing comparable 
effectiveness. Two studies comparing oral diclofenac with a topical prepara-
tion of the drug [51, 52] found no difference in pain scores or physical function. 
Furthermore, those in the topical treatment arm had a much lower incidence of 
severe gastrointestinal side effects, deranged liver function tests and abnormal 
creatinine clearance [51, 52]. These results were replicated in another study compar-
ing oral and topical treatment with ibuprofen for knee osteoarthritis [50].
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On the whole, topical NSAID use is associated with fewer systemic adverse 
events [42, 46, 51, 52] than oral preparations. The main side effect associated with 
topical NSAID use is local skin irritation, which has been reported in up to 39.3% 
of patients [53]. However, these skin reactions occur in equal measure with placebo 
gel application indicating that they may not be related to the active drug itself [46]. 
Other studies also suggest that skin reactions may be more common with solutions 
containing DMSO than diclofenac sodium gel (DSG) [44]. There is some contradic-
tory evidence regarding their safety in older patients as some studies have found the 
rate of gastrointestinal side effects in the over 50s to be as high as 15% [53].
Overall, the data suggest that topical NSAIDs may be considered as first-line 
therapy for osteoarthritis as they are efficacious and associated with fewer adverse 
events. As with oral use, however, there should still be caution about their long-
term application in the elderly as these patients are known to be more prone to 
adverse events.
2.5 Other topical treatments
Topical capsaicin cream has been used to treat a multitude of different painful 
conditions including osteoarthritis, inflammatory arthritis and neuropathic pain. 
Derived from chilli peppers, capsaicin is a lipophilic alkaloid that acts as a local 
irritant. It activates local pain receptors (c-nociceptors) leading to the release of 
substance P [54]. This in turn causes local irritation in the initial phase of treat-
ment. With repeated use, however, levels of substance P are depleted, leading to 
desensitisation of the pain fibres and hypoalgesia [55].
In clinical practice, capsaicin is more effective than placebo for the treatment of 
chronic pain but compares less favourably with other treatments. In a meta-analysis 
comparing capsaicin with plaster for instance, capsaicin was found to be only 
marginally effective [56]. Other drawbacks include the need to use the cream four 
times a day for maximum benefit, as well as the local irritation and burning sensa-
tion when the cream is applied (occurring in up to 40% of patients) [57, 58]. These 
problems cause 10% of patients to discontinue treatment [56]. In view of this, 
topical capsaicin should be used in conjunction with more traditional treatments.
Other topical treatments include the use of salicylate or nicotine esters, which 
can be classed as local counterirritants and rubefacients, and lidocaine patches. 
Rubefacients cause localised vasodilatation and reddening of the skin that 
result in a local sensation of warmth, which often palliates pain. Irritation of the 
sensory nerve endings in underlying muscle and tissue is a by-product of their 
application and thought to modify pain pathways [59], but their main action is 
regional skin irritation.
The available evidence does not support their use for acute injuries or for chronic 
conditions such as osteoarthritis, though they are relatively well tolerated in the 
short term [60]. When compared to topical NSAIDs, counterirritants performed 
poorly [60]. This has led to numerous recommendations advising the discontinu-
ation of routine rubefacient prescriptions in England, with patients signposted to 
alternative, more efficacious local treatments [61].
Lidocaine patches are not currently licensed for use in osteoarthritis in the 
United Kingdom, instead being more commonly utilised in the context of post-
herpetic neuralgia. There is some anecdotal evidence for their efficacy in OA, 
however [62]. Lidocaine forms cations following ionisation with hydrogen ions and 
reversibly inhibits voltage-gated sodium channels on the internal surface of neuro-
nal surface membranes when bound [63]. This prevents an influx of sodium cations 
(Figure 2) which in turn leads to a failure of nerve depolarisation resulting in the 
diminished pain signalling that has been observed in some clinical trials.
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One open-label multicentre study investigated the effect of application of lido-
caine to the area of maximal OA pain in OA of the knee [62]. A 5% lidocaine patch 
was applied for 12 hours at the same time each day for a period of 2 weeks with 
significant improvement in pain and functional scores when this treatment was used 
as an adjunct to more conventional systemic analgesia. Furthermore, there were mini-
mal adverse effects seen, and the treatment was well tolerated in the patient cohort.
Clearly, randomised control trials are required to support the anecdotal data, as 
a sustained benefit has yet to be proven. It should also be noted that the symptom-
atic improvement observed was related to the use of a lidocaine patch as an adjunct 
to therapy, rather than a lone therapeutic agent in the management of OA. As in the 
case of capsaicin or rubefacients, lidocaine acts as a painkiller but has no disease-
modifying capacity.
3. Local injections
3.1 Intra-articular corticosteroids
Intra-articular corticosteroid injections are frequently used to treat osteoarthri-
tis. They work locally via anti-inflammatory effects, inhibiting the inflammatory 
cascade predominantly through the glucocorticoid receptor (GR) on both genomic 
and non-genomic levels (Figure 3). The genomic pathway largely comprises GR 
binding leading to the recruitment of complexes that influence the activity of RNA 
polymerase II. This affects gene transcription and repression. The GR also directly 
binds subunits of transcription factors such as NF-κB and activator protein-1 
(AP-1), interfering with their activation and inhibiting the production of pro-
inflammatory cytokines.
The non-genomic pathway is set in motion within seconds of GR binding. 
Various signalling cascades are activated such as those that inhibit phospholipase A2 
activation and subsequent arachidonic acid release. These result in a downregulation 
of cyclic endoperoxides that are key components of the inflammatory response [65].
Local injection avoids many of the systemic problems associated with oral cor-
ticosteroid use and allows delivery of high doses to the affected tissue. Response to 
IA injection, however, does not appear to be dependent on inflammation within the 
affected joint itself [66]. Additional studies looking at whether inflammation detected 
on ultrasound predicted clinical response found that those without inflammatory 
Figure 2. 
The effect of lidocaine on a voltage-gated sodium channel. Abbreviations: LA, lidocaine; Na, sodium;  
H, hydrogen, ECF, extracellular fluid, ICF, intracellular fluid.
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change fared better in response to IA injection than those with evidence of inflam-
mation. Furthermore, the presence of synovial thickening, synovial fluid volume and 
white cell count did not predict better response to IA injection [66, 67]. In knee OA, 
joint aspiration prior to IA injection appears to provide greater symptomatic benefit 
[67]. This is partly due to anatomical confirmation on prior aspiration and concen-
trated drug delivery due to a lower volume of overall synovial fluid [68].
Commonly, IA injections are diluted with local anaesthetic to provide immediate 
relief, ensure accurate drug delivery and allow even dispersal of the drug within the 
joint due to the larger volume [69]. Frequently used corticosteroids in IA injections 
include hydrocortisone acetate (HCA), methylprednisolone acetate (MPA) and 
triamcinolone acetonide (TCA). These vary in solubility with the HCA being the 
most soluble of these three and TCA the least soluble. Less soluble preparations are 
longer acting and theoretically provide more long-term relief.
This effect is not always observed in clinical practice, however. In one ran-
domised control trial comparing MPA (more soluble and shorter acting) and TCA in 
knee osteoarthritis, greater improvement in pain scores was found in the TCA group 
at 3 weeks than in MPA, although there was no difference between the two groups at 
8 weeks [70]. There was also no significant difference in functional scores [70].
Further studies have investigated whether IA steroid injections provide symp-
tomatic or functional benefit in knee osteoarthritis [66, 67, 71, 72]. These demon-
strated short-term improvement in pain generally up to 4 weeks, though a small 
proportion of patients reported benefit to 6 weeks. Conversely, no improvement 
in function was seen when compared to placebo, and follow-up beyond 6 weeks 
did not reveal longer-lasting benefits. These results were further corroborated in a 
Cochrane systematic review [73]. This suggests IA steroid injections should be used 
as a short-term bridging treatment to resolve acute painful flares pending further 
intervention such as physiotherapy or surgery. Similar trials observing IA injections 
in the hip echo the results of those studies focusing on the knee: patients gained 
rapid and short-lived pain relief following injection, but these benefits were not 
maintained beyond 1 month [74, 75].
Other studies, focused specifically on another joint commonly affected by osteo-
arthritis, the first carpometacarpal (CMC) joint, uncovered more variable results 
related to long-term relief. In one study of 40 patients, no benefit was observed 
between IA steroid injection when compared to placebo [76]. Unsurprisingly, 
patients less likely to have sustained long-term benefits had more significant 
radiographic appearances (increased number of osteophytes and advanced joint 
space narrowing) [77]. In patients with less advanced disease, IA first CMC joint 
injection could provide symptomatic relief for up to 18 months following injection 
and splinting [77].
Figure 3. 
Summary of the glucocorticoid signalling pathways (reproduced from Ref. [64]). Abbreviations: GR, 
glucocorticoid receptor; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; AP-1, activator 
protein-1; PI3K, phosphoinositide 3-kinase; AKT, RAC-alpha serine/threonine-protein kinase; MAPKs, 
mitogen-activated protein kinases.
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Although IA injections avoid the potentially toxic side effects of systemic 
steroids, they are not without risks themselves. All patients undergoing IA injec-
tion should be consented for the risk of infection, although this is a rare event 
(incidence reported between 1 in 3000 and 1 in 50,000) [78] and may be clinically 
difficult to differentiate from an injection-induced crystal arthritis which can occur 
in 2–6% of patients [67, 71]. In general, septic arthritis following IA injection occurs 
3–4 days post procedure. There is a risk of lipoatrophy at the site of injection (esti-
mated 0.6% of patients) [79], although this can be reduced by using shorter-acting 
preparations. Other serious local adverse events include tendon rupture, muscle 
wasting and local depigmentation. These risks can be minimised by performing 
image-guided injections where possible.
Systemic adverse events are rare with local corticosteroid injections, but as there 
is evidence for systemic absorption, they do still occur [80]. The most common is 
flushing which occurs in up to 40% of patients [81]. There have been reported inci-
dents of unstable diabetic glycaemic control postinjection but this tends to be minor 
and usually settles [82]. Studies looking at the endocrine axis in patients who had 
received IA steroid injections found that serum cortisol dipped 24–48 hours after 
IA injection and took up to 4 weeks to return to baseline [80]. Major complications, 
such as steroid-induced osteoporosis, have not been observed, however [82].
Studies in animals have suggested that IA steroids can induce chondrocyte 
degeneration [83], but prospective clinical trials where patients received regular 
IA injections have failed to demonstrate an increased rate of cartilage loss [84]. 
There are also limited data to support a significant increased risk of osteonecrosis in 
injected joints. Nevertheless, repeated IA injections offer no long-term benefit [73] 
and should generally be avoided except for rapid pain relief in the short term in the 
absence of superior alternatives.
3.2 Intra-articular hyaluronic acid/hyaluronan
Hyaluronic acid (HA), also known as hyaluronan, is a large glycosaminoglycan 
molecule found in synovial and cartilage extracellular matrix (ECM). It is produced 
by synoviocytes, chondrocytes and fibroblasts and functions as both a lubricant 
and a means to maintain hydration within the joint [85]. Studies have shown that 
osteoarthritic joints have decreased hyaluronan content in the synovial fluid [86] 
and therefore IA injection with a synthetic analogue was a method developed to 
restore the function in degenerative joints.
Chondroprotection is the most frequent mechanism proposed in favour of the 
use of IA-HA [87]. This term specifically refers to the reduction of chondrocyte 
apoptosis as well as an increase in chondrocyte proliferation that occurs when 
HA binds to CD44 receptors. This results in inhibition of the well-known pro-
inflammatory cytokine interleukin (IL)-1β through induction of mitogen-activated 
protein kinase phosphatase (MKP)-1 [88].
Synthetic preparations of HA closely mimic endogenous molecules. Later 
preparations contain cross-linked hyaluronan in order to achieve greater elasticity 
and viscosity. In theory, this confers greater intra-articular durability of the solu-
tion. Preparations with a higher molecular weight also seem to be more beneficial 
than those with a lower weight [89]. This may be related to the difference in volume 
required for injection, the number of injections required and the intra-articular 
durability of the solution.
Multiple studies have been conducted investigating the efficacy of IA injections 
of hyaluronans in osteoarthritis, mostly affecting the knee, and the evidence to 
support their use has been mixed. In general, HA appears to be better than placebo 
in improving pain scores, function and patient global assessment in the context of 
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knee osteoarthritis [90]. The greatest clinical benefit is achieved at week 5–13 after 
a course of treatment of several injections. However, one of the drawbacks of the 
available data is the wide variability in trial design, frequency of injections and 
molecular weight of the administered synthetic product. Additionally, in hip OA, 
HA injections were not superior to placebo or corticosteroid injections in reducing 
pain or improving function [91]. There were similar findings in studies looking at 
OA of the hand [92].
Though HA is relatively safe, its use is restricted by the relatively high cost 
of the treatment [87]. It is generally reserved for knee osteoarthritis and, like 
corticosteroid, is offered either as a holding measure until more definitive treat-
ment can be undertaken (e.g. surgery) or in patients for whom such treatment is 
inappropriate.
3.3 Subcutaneous and soft tissue injections
Trigger points are localised areas of tenderness and thickening in the soft tissues. 
They are typically located proximal to an inflamed or painful joint such as the 
rectus femoris in patients with knee OA and paraspinal regions in the cervical and 
lumbar spine [93]. They have also been described as interstitial fibrositis, myofasci-
itis and myofascial trigger points [94–96]. The aetiology and pathogenesis of trigger 
points are unknown.
Trigger point injections (TPI) have been used as a way of alleviating pain and 
discomfort associated with these areas of thickening. This can be via direct injec-
tion of medication (e.g. local anaesthetic and/or corticosteroid) into the point of 
tenderness or indirect needling of the soft tissue in that area. The trigger point is 
identified as the maximal area of tenderness in the muscle and is usually isolated by 
the thumb and forefinger to prevent movement in the underlying muscle. A small 
sterile needle is then introduced into the area, and the substance is injected directly 
within. Alternatively, a dry needle approach (without medication) can be used. If 
the injection is performed correctly, there is typically an initial acute worsening of 
pain associated with muscle spasm [97].
A systematic review of TPI in the management of chronic musculoskeletal 
pain revealed an improvement in symptoms when used exclusively [98]. This was 
irrespective of the injectant used [98]. The addition of a local anaesthetic, however, 
has been found to reduce the pain and irritation that is temporarily caused by the 
procedure [96].
There are limited data on the efficacy of TPI in the treatment of osteoarthritis. 
One study found that TPI in conjunction with IA corticosteroid was more effective 
than IA injection alone evidenced in both pain and functional scores [99]. Other 
studies have looked at TPI as sole treatment for OA, but this does not reflect clinical 
practice. Overall, TPI is safe and can be used as additional therapy in OA, though 
consideration should be made on a case-by-case basis.
Medication used in TPI includes local anaesthetic, corticosteroids, anti-inflamma-
tories such as acetylsalicylate and ketorolac, as well as saline and water [96, 100–104]. 
There have also been several studies looking at the use of subcutaneous salicylate 
therapy for OA. In one trial 40 patients with OA of the first CMC joint [105] were ran-
domised to receive either sham injection or subcutaneous injection with salicylate into 
trigger points. Patients were assessed blindly at 3, 7 and 13 weeks. Pain scores were 
significantly lower in those treated with salicylate than with sham injections [105].
The mechanism of action of subcutaneous salicylate injections is unclear, 
particularly as the site of injection is not within the affected joint. One theory is that 
salicylate may alter central sensitisation, and this is supported by the immediate 
relief patients report following injection. An alternative hypothesis is that the local 
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effect of salicylate modifies the neurogenic control of inflammation, which may be 
abnormal in diseases that affect musculoskeletal structures such as OA [106, 107]. 
Changes in the expression and transport of neurogenic peptides may be induced by 
the local irritant effect of salicylate [108]. Systemic anti-inflammatory effects are 
unlikely, since the benefits are generally not observed in distant sites [105].
There is a degree of overlap between TPI and acupuncture in that the injection 
sites are standard acupuncture locations. Acupuncture involves the insertion of 
fine filiform needles at or near the tender anatomical site or sometimes at distant 
acupuncture “points”. In a variation of this, the needles are sometimes stimulated 
electronically or with heat. Patients typically receive six or more sessions for a 
complete course of treatment. A systematic review of 393 patients with OA found 
acupuncture significantly improved pain but not function when compared to sham 
acupuncture [109–116]. In addition, results were no better than standard treatment 
with physiotherapy or being on a waiting list to receive acupuncture [109, 112]. 
There was also no additional benefit seen when using acupuncture as an adjunct to 
standard therapy with exercise and advice [115]. Moreover, there is little evidence 
for long-term benefit following acupuncture treatment, as symptomatic improve-
ments tend to last up to 12 weeks only [109, 112]. Acupuncture is relatively safe, 
however, with minimal risks of serious side effects [113–116].
4. Orthoses
Osteoarthritic joints may be reinforced by various forms of external support 
known as orthoses. These applied devices modify the structural and functional 
characteristics of the neuromusculoskeletal system. Benefit can be obtained by 
adjusting alignment, reducing stress or load, providing shock absorption or simply 
resting the joint.
Orthoses such as braces, splints and elasticated sleeves are frequently used in OA 
of the hand and knee. Thumb and wrist splints are employed in hand OA, whilst 
knee sleeves and unloading braces can be useful adjuncts in knee OA. Medial patel-
lar strapping can be specifically helpful for patellar maltracking [117]. Shoe insoles 
may be of benefit in OA affecting the ankle and knee and can sometimes alleviate 
symptoms caused by OA of the hip. Insoles can be differentiated into cushioned 
or neutral subtypes, which have shock-absorbing properties, and wedged insoles, 
which offset varus or valgus deformities as well as modulate mechanical stress.
For OA of the knee and ankle, the main purpose of orthoses and insoles is to 
support a joint that is unstable and to help correct alignment [118]. They can modify 
load bearing, contribute to pain reduction and improve physical function. There 
is also some evidence that they can improve proprioception [119] and they may 
slow disease progression [120]. They are especially useful for mild or moderate 
uni-compartmental knee OA where there may be varying degrees of instability and 
malalignment [121, 122].
Unloading knee braces are designed to reduce the load transmitted to the 
affected compartment by applying an external valgus or varus force. Symptomatic 
relief is achieved by stabilising the joint, increasing joint opening and reducing local 
muscle contraction [120]. One study [123] demonstrated that patients with medial 
compartment knee OA treated with unloading knee braces had better functional 
and symptomatic outcomes at 6 months. These results were not replicated in other 
studies [124] although there is evidence they can improve quadricep strength and 
gait symmetry [125].
The main disadvantage of these braces is poor tolerability due to the weight and 
heat of the device. In one study, 41% of patients complained of skin irritation [126], 
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and up to 20% of patients discontinue use within 6 months [127]. Overall, there is 
limited evidence that braces or insoles provide an additional beneficial effect for 
knee OA when compared with medical treatment alone [128].
On the other hand, splinting of the thumb CMC joint has been found to be 
helpful in improving function and pain [129]. CMC joint OA contributes more to 
pain and disability than interphalangeal joint OA [130], and thus splinting of the 
CMC joint is logical. In a systematic review in 2010, CMC splinting was found to 
improve function and grip strength [129]. Further RCT data has corroborated this 
finding and demonstrated sustained benefit at 12 months [131]. However, these 
splints are inevitably somewhat cumbersome to wear and inhibit many day-to-day 
manual functions.
In general, splinting might be useful for symptomatic relief and may even 
improve function with prolonged use in appropriately selected patients.
5. Mesenchymal stem cells
The next frontier in local osteoarthritis management is likely to involve the 
use of mesenchymal stem cells (MSCs). These pluripotent cells have the capacity 
to differentiate into a variety of cell types, including chondrocytes, making their 
potential use in osteoarthritis a highly attractive prospect [132].
MSCs can undergo chondrogenesis and have been combined with a number of 
materials that support this differentiation, including the aforementioned polymer 
HA [133]. Neocartilage formation, hypertrophy and matrix calcification, as is seen 
in the terminal differentiation of hypertrophic chondrocytes in the growth plate, 
have been observed in vitro [134] and in mice [135] resulting in the efficient forma-
tion of bone. There are various hypotheses as to how this might occur. They include 
the inhibition of apoptosis [136] and subsequent immunomodulation [137] both of 
which are currently being tested in murine models of OA.
Clearly, translation to human studies is required before MSCs become a viable 
clinical option in the local treatment of OA, but there is understandable optimism 
that this therapy may herald a long-term solution to slowing the rate of articular 
cartilaginous degeneration and subchondral bone remodelling.
6. Conclusion
There are numerous local treatments for osteoarthritis. The majority of local 
therapies are safe and avoid any significant systemic adverse effects. They mostly 
provide symptomatic relief. In many cases this is of undoubted value to individual 
patients, particularly during the inflammatory phase of OA. In some cases there 
may be a useful placebo effect. In general, these therapies should be used as 
adjuncts to physiotherapy and systemic analgesia which remain the mainstay of 
conservative OA management. The choice of local therapy in an individual patient 
should be guided by the severity of disease, local experience and patient preference.
Some of these treatments, for instance, IA injections and orthoses, are well 
established and have been used in clinical practice for many decades. Other more 
novel approaches have been developed such as local laser therapy and subcutaneous 
sodium salicylate injections. However, for all the therapies described in this chapter, 
there are only limited data to demonstrate long-term benefit. Further studies are 
required to establish their lasting value. In the meantime these treatments remain 
valuable as temporary measures for many patients, particularly those with flares of 
symptoms or who are awaiting more definitive treatment.
Osteoarthritis
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